海王生物(000078) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥8,065,410,460.99, a decrease of 23.52% compared to ¥10,545,449,942.88 in the same period last year[8] - Net profit attributable to shareholders was ¥79,153,581.35, down 40.07% from ¥132,077,118.26 year-on-year[8] - Basic earnings per share decreased by 41.67% to ¥0.0287 from ¥0.0492 in the same period last year[8] - Operating revenue decreased by 23.52% year-on-year, primarily due to a decline in sales impacted by the COVID-19 pandemic[20] - Net profit decreased by 31.58% year-on-year, mainly due to the decline in sales caused by the COVID-19 pandemic[20] - The total operating revenue for the current period is 1,256,593.77, a decrease of 31.2% compared to 1,826,561.04 in the previous period[62] - The net profit for the current period is 138,300,327.25, down 31.6% from 202,135,057.50 in the previous period[58] - The operating profit for the current period is 204,836,613.36, a decrease of 31.1% compared to 297,166,042.91 in the previous period[58] - The total profit for the current period is 195,467,594.97, down 34.7% from 299,122,493.86 in the previous period[58] Cash Flow - The net cash flow from operating activities was ¥26,977,175.30, reflecting a significant decline of 61.16% compared to ¥69,452,343.45 in the previous year[8] - The net cash flow from operating activities decreased by 61.16% year-on-year, primarily due to an increase in prepaid accounts[20] - Cash inflows from operating activities totaled 9,762,271,293.77 CNY, down from 13,395,769,110.76 CNY year-over-year, representing a decrease of approximately 27.5%[69] - Cash outflows from operating activities amounted to 9,735,294,118.47 CNY, compared to 13,326,316,767.31 CNY in the previous period, indicating a decrease of about 27.5%[72] - The net cash flow from financing activities increased by 22.24% year-on-year, primarily due to new anti-epidemic loans[20] - The net cash flow from financing activities was 898,965,601.13 CNY, compared to 735,393,491.67 CNY in the previous period, showing an increase of about 22.2%[75] - The net cash flow from investing activities increased by 73.72% year-on-year, mainly due to a decrease in external investments[20] - The net cash flow from investing activities was -31,632,475.71 CNY, an improvement from -120,354,018.00 CNY in the prior year[72] Assets and Liabilities - Total assets increased by 6.11% to ¥43,683,252,763.21 from ¥41,168,283,718.59 at the end of the previous year[8] - Current liabilities totaled CNY 34,050,193,981.13, an increase from CNY 31,828,994,088.35[44] - Total liabilities amounted to CNY 35,715,479,118.56, up from CNY 33,319,372,797.95[44] - The company’s retained earnings increased to CNY 1,257,371,452.45 from CNY 1,178,217,871.10[44] - The total equity attributable to shareholders was CNY 6.25 billion, with retained earnings of CNY 1.18 billion[86] - The company reported a contract liability of CNY 305 million due to the new revenue recognition standards effective January 1, 2020[86] Government Support and Subsidies - The company received government subsidies amounting to approximately ¥15,827,624.01, including about ¥5.83 million for import and export subsidies[8] - The other income for the current period is 15,827,624.01, an increase of 57.5% compared to 10,061,881.28 in the previous period[58] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 230,797, with the largest shareholder holding 44.03% of the shares[12] Research and Development - The research and development expenses for the current period are 7,837,944.44, a decrease of 24.2% from 10,334,180.91 in the previous period[58] - The company received FDA approval for its independently developed tumor vascular occlusion agent HW130 injection to conduct Phase I clinical trials in the U.S.[21] Miscellaneous - The company reported a non-recurring loss of ¥172,262.54 from the disposal of non-current assets[8] - The first quarter report was not audited[94]